1 CURRICULUM VITAE – DANIEL ABRAMOWICZ ... - Oxford Journals

ABRAMOWICZ D.
Major Histocompatibility Complex Class 1 Chain-Related Antigen A Antibodies:
Sensitizing Events and Impact on Renal Graft Outcomes.
Transplantation. 2010 May 11.
130. GLOTZ D, CHARPENTIER B, ABRAMOwICZ D, LANG P, ROSTAING L, RIFLE
G, VANRENTERGHEM Y, BERTHOUX F, BOURBIGOT B, DELAHOUSSE M,
CHALOPIN JM, CASSUTO E, LEFRANÇOIS N.
Thymoglobulin induction and sirolimus versus tacrolimus in kidney transplant recipients
receiving mycophenolate mofetil and steroids.
Transplantation. 2010 Jun 27;89(12):1511-7.
131. KIANDA MN, WISSING KM, BROEDERS NE, LEMY A, GHISDAL L, HOANG AD,
MIKHALSKI D, DONCKIER V, VEREERSTRAETEN P, ABRAMOWICZ D.
Ineligibility for renal transplantation: prevalence, causes and survival in a consecutive
cohort of 445patients.
Clin Transplant. 2011 Jul;25(4):576-83.
132. LEMY A, TOUNGOUZ M, ABRAMOWICZ D. Bortezomib: a new player in pre- and
post-transplant desensitization?
Nephrol Dial Transplant. 2010 Nov;25(11):3480-9
133. KRÄMER BK, CHARPENTIER B, BÄCKMAN L, SILVA HT Jr, MONDRAGON,
RAMIREZ G, CASSUTO-VIGUIER E, MOURAD G, SOLA R, RIGOTTI P, MIRETE
JO; Tacrolimus Prolonged Release Renal Study Group. Tacrolimus once daily
(ADVAGRAF) versus twice daily (PROGRAF) in de novo renal transplantation: a
randomized phase III study. Am J Transplant. 2010 Dec;10(12):2632-43.
134. HOUGARDY JM, BROEDERS N, KIANDA M, MASSART A, MADHOUN P, LE
MOINE A, HOANG AD, MIKHALSKI D, WISSING KM, ABRAMOWICZ D.
Conversion from Prograf to Advagraf among kidney transplant recipients results in
sustained decrease in tacrolimus exposure.
Transplantation 2011 Mar 15;91(5):566-9.
135. HUMAR A, LIMAYE AP, BLUMBERG EA, HAUSER IA, VINCENTI F, JARDINE
AG, ABRAMOWICZ D, IVES JA, FARHAN M, PEETERS P. Extended valganciclovir
prophylaxis in D+/R-kidney transplant recipients is associated with long-term reduction
in cytomegalovirus disease: two-year results of the IMPACT study.
Transplantation 2010 Dec 27;90(12):1427-31.
27